ArticlebioRxiv : the preprint server for biology2025
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.
David J Wisniewski et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.